209 related articles for article (PubMed ID: 23318765)
41. Insight into the selectivity of arsenic trioxide for acute promyelocytic leukemia cells by characterizing Saccharomyces cerevisiae deletion strains that are sensitive or resistant to the metalloid.
Dilda PJ; Perrone GG; Philp A; Lock RB; Dawes IW; Hogg PJ
Int J Biochem Cell Biol; 2008; 40(5):1016-29. PubMed ID: 18160327
[TBL] [Abstract][Full Text] [Related]
42. Arsenic trioxide.
Litzow MR
Expert Opin Pharmacother; 2008 Jul; 9(10):1773-85. PubMed ID: 18570609
[TBL] [Abstract][Full Text] [Related]
43. Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide.
Zheng Y; Mao YF; Zhao HJ; Chen L; Wang LN; Zhang YX; Hu J; Li JM; Li XY; Zhu HM
Exp Hematol Oncol; 2021 Feb; 10(1):10. PubMed ID: 33549147
[TBL] [Abstract][Full Text] [Related]
44. A colorimetric method for the determination of arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid in biological and environmental samples.
Lakso JU; Rose LJ; Peoples SA; Shirachi DY
J Agric Food Chem; 1979; 27(6):1229-33. PubMed ID: 575651
[No Abstract] [Full Text] [Related]
45. A feasible method for As speciation in several types of seafood by LC-ICP-MS/MS.
Schmidt L; Landero JA; Novo DR; Duarte FA; Mesko MF; Caruso JA; Flores EMM
Food Chem; 2018 Jul; 255():340-347. PubMed ID: 29571485
[TBL] [Abstract][Full Text] [Related]
46. Torsemide increases arsenic concentrations by inhibition of multidrug resistance protein 4 in arsenic trioxide treated acute promyelocytic leukemia patients.
Lv J; Wu M; Pang C; Duan R; Zhang H; Tian S; Yang H; Hai X
Biomed Pharmacother; 2023 Jul; 163():114858. PubMed ID: 37172335
[TBL] [Abstract][Full Text] [Related]
47. Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia.
Calleja EM; Warrell RP
Curr Oncol Rep; 2000 Nov; 2(6):519-23. PubMed ID: 11122887
[TBL] [Abstract][Full Text] [Related]
48. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
Muto A; Kizaki M; Kawamura C; Matsushita H; Fukuchi Y; Umezawa A; Yamada T; Hata J; Hozumi N; Yamato K; Ito M; Ueyama Y; Ikeda Y
Leukemia; 2001 Aug; 15(8):1176-84. PubMed ID: 11480559
[TBL] [Abstract][Full Text] [Related]
49. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
[TBL] [Abstract][Full Text] [Related]
50. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment.
Sweeney CJ; Takimoto C; Wood L; Porter JM; Tracewell WG; Darwish M; D'Andrea DM; Remick SC
Cancer Chemother Pharmacol; 2010 Jul; 66(2):345-56. PubMed ID: 19911123
[TBL] [Abstract][Full Text] [Related]
51. Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide.
Mathews V; Balasubramanian P; Shaji RV; George B; Chandy M; Srivastava A
Br J Haematol; 2001 Apr; 113(1):257-8. PubMed ID: 11360894
[No Abstract] [Full Text] [Related]
52. Metabolism, toxicity and anticancer activities of arsenic compounds.
Khairul I; Wang QQ; Jiang YH; Wang C; Naranmandura H
Oncotarget; 2017 Apr; 8(14):23905-23926. PubMed ID: 28108741
[TBL] [Abstract][Full Text] [Related]
53. On-line reversed-phase liquid chromatography hydride generation emission spectrometry: speciation of arsenic in urine of patients intravenously treated with As2O3.
Do B; Alet P; Pradeau D; Poupon J; Guilley-Gaillot M; Guyon F
J Chromatogr B Biomed Sci Appl; 2000 Apr; 740(2):179-86. PubMed ID: 10821403
[TBL] [Abstract][Full Text] [Related]
54. Survivin isoform expression in arsenic trioxide-treated acute promyelocytic leukemia cell line and patients: The odd expression pattern of survivin-2α.
Zaki Dizaji M; Ghaffari SH; Hosseini E; Alizadeh N; Rostami S; Momeny M; Alimoghaddam K; Ghavamzadeh A
Asia Pac J Clin Oncol; 2017 Apr; 13(2):e21-e30. PubMed ID: 27770503
[TBL] [Abstract][Full Text] [Related]
55. Arsenic speciation in rice samples for trace level determination by high performance liquid chromatography-inductively coupled plasma-mass spectrometry.
Kara S; Chormey DS; Saygılar A; Bakırdere S
Food Chem; 2021 Sep; 356():129706. PubMed ID: 33831825
[TBL] [Abstract][Full Text] [Related]
56. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Huan SY; Yang CH; Chen YC
Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
[TBL] [Abstract][Full Text] [Related]
57. The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia.
Zhu H; Hu J; Chen L; Zhou W; Li X; Wang L; Zhao X; Zhang Y; Zhao H; Wang A; Chen Y; Sun H; Chen Q; Chen Y; Zhao W; Mi J; Shen Z; Wang Z; Chen Z; Chen S; Li J
Blood; 2016 Sep; 128(11):1525-8. PubMed ID: 27402972
[No Abstract] [Full Text] [Related]
58. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy.
Au WY; Tam S; Fong BM; Kwong YL
Blood; 2008 Nov; 112(9):3587-90. PubMed ID: 18703707
[TBL] [Abstract][Full Text] [Related]
59. In vitro exposure of acute promyelocytic leukemia cells to arsenic trioxide (As2O3) induces the solitary expression of CD66c (NCA-50/90), a member of the CEA family.
Di Noto R; Boccuni P; Costantini S; Dello Russo A; Lo Pardo C; Copia C; Annunziata M; Cimino R; Ferrara F; Del Vecchio L
Tissue Antigens; 1999 Dec; 54(6):597-602. PubMed ID: 10674975
[TBL] [Abstract][Full Text] [Related]
60. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
Lam MS; Ignoffo RJ
Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
